In urothelial cancer, as in most metastatic solid tumors, your optimal outcome comes from up front therapy, "saving things for later" is not usually the best management approach. As noted by the good Dr. @Kuzel, given the info we have regarding EV 302 (press release), this regimen may become an impo...

The standard of care for the treatment of metastatic urothelial cancer for several decades has been first line therapy with a cisplatin based combination regimen. For patients not eligible to receive cisplatin, a carboplatin doublet has often been recommended although in multiple studies, overall su...